BioSyent Inc. (CVE:RX – Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$13.97 and traded as low as C$13.85. BioSyent shares last traded at C$13.95, with a volume of 87,690 shares.
BioSyent Trading Up 0.6%
The stock’s fifty day moving average price is C$14.37 and its 200 day moving average price is C$13.97. The company has a quick ratio of 6.91, a current ratio of 1.89 and a debt-to-equity ratio of 11.66. The stock has a market cap of C$158.08 million, a PE ratio of 17.79 and a beta of 1.02.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Featured Stories
- Five stocks we like better than BioSyent
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
